Used as a selective inhibitor of HSF1 (Heat Shock Factor 1), KRIBB11 is widely applied in cancer research to disrupt the heat shock response in tumor cells. It suppresses the expression of heat shock proteins, which cancer cells rely on for survival under stress, thereby promoting apoptosis. Studies have shown its effectiveness in reducing growth in various cancer cell lines, including breast, liver, and lung cancers. KRIBB11 is also used to investigate cellular stress pathways and to develop combination therapies with other anticancer agents, enhancing their efficacy by weakening cancer cell defense mechanisms.